These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 20446896)
21. [Usefulness of BTA Stat test (Bard) in the diagnosis of bladder cancer. Preliminary results and comparison with cytology and cystoscopy]. Gutiérrez Baños JL; Martín García B; Hernández Rodríguez R; Portillo Martín JA; Correas Gómez MA; del Valle Schaan JI; Roca Edreira A; Villanueva Peña A; Gutíerrez García R; De Diego Rodríguez E; Rado Velázquez MA Arch Esp Urol; 1998 Oct; 51(8):778-82. PubMed ID: 9859583 [TBL] [Abstract][Full Text] [Related]
22. Risk stratification for bladder tumor recurrence, stage and grade by urinary nuclear matrix protein 22 and cytology. Shariat SF; Casella R; Wians FH; Ashfaq R; Balko J; Sulser T; Gasser TC; Sagalowsky AI Eur Urol; 2004 Mar; 45(3):304-13; author reply 313. PubMed ID: 15036675 [TBL] [Abstract][Full Text] [Related]
23. [NMP-22 test. Is it useful in the follow-up of patients with superficial bladder tumor?]. Pérez García FJ; Eyo A; Escaf Barmadah S; Fernández Gómez JM Arch Esp Urol; 2002 Dec; 55(10):1201-8. PubMed ID: 12611217 [TBL] [Abstract][Full Text] [Related]
26. Use of urinary biomarkers for bladder cancer surveillance: patient perspectives. Yossepowitch O; Herr HW; Donat SM J Urol; 2007 Apr; 177(4):1277-82; discussion 1282. PubMed ID: 17382711 [TBL] [Abstract][Full Text] [Related]
27. Evaluation of two new urinary tumor markers: bladder tumor fibronectin and cytokeratin 18 for the diagnosis of bladder cancer. Sánchez-Carbayo M; Urrutia M; González de Buitrago JM; Navajo JA Clin Cancer Res; 2000 Sep; 6(9):3585-94. PubMed ID: 10999749 [TBL] [Abstract][Full Text] [Related]
28. Recent improvements in the detection and treatment of nonmuscle-invasive bladder cancer. Kausch I; Doehn C; Jocham D Expert Rev Anticancer Ther; 2006 Sep; 6(9):1301-11. PubMed ID: 17020462 [TBL] [Abstract][Full Text] [Related]
29. NMP22: a sensitive, cost-effective test in patients at risk for bladder cancer. Zippe C; Pandrangi L; Potts JM; Kursh E; Novick A; Agarwal A Anticancer Res; 1999; 19(4A):2621-3. PubMed ID: 10470205 [TBL] [Abstract][Full Text] [Related]
30. Neural network using combined urine nuclear matrix protein-22, monocyte chemoattractant protein-1 and urinary intercellular adhesion molecule-1 to detect bladder cancer. Parekattil SJ; Fisher HA; Kogan BA J Urol; 2003 Mar; 169(3):917-20. PubMed ID: 12576812 [TBL] [Abstract][Full Text] [Related]
31. Suspicious urine cytology (class III) in patients with bladder cancer: should it be considered as negative or positive? Raitanen MP; Aine RA; Kaasinen ES; Liukkonen TJ; Kylmälä TM; Huhtala H; Tammela TL; Scand J Urol Nephrol; 2002; 36(3):213-7. PubMed ID: 12201938 [TBL] [Abstract][Full Text] [Related]
32. Immunocyt and the HA-HAase urine tests for the detection of bladder cancer: a side-by-side comparison. Hautmann S; Toma M; Lorenzo Gomez MF; Friedrich MG; Jaekel T; Michl U; Schroeder GL; Huland H; Juenemann KP; Lokeshwar VB Eur Urol; 2004 Oct; 46(4):466-71. PubMed ID: 15363562 [TBL] [Abstract][Full Text] [Related]
33. Comparative evaluation of the diagnostic performance of the BTA stat test, NMP22 and urinary bladder cancer antigen for primary and recurrent bladder tumors. Giannopoulos A; Manousakas T; Gounari A; Constantinides C; Choremi-Papadopoulou H; Dimopoulos C J Urol; 2001 Aug; 166(2):470-5. PubMed ID: 11458049 [TBL] [Abstract][Full Text] [Related]
34. [Clinical value of combined detection with urinary bladder cancer antigen, hyaluronic acid and cytokeratin 20 in diagnosis of bladder cancer]. Pu XY; Wang ZP; Chen YR; Wu YL; Wang HP; Wang XH Ai Zheng; 2008 Sep; 27(9):970-3. PubMed ID: 18799038 [TBL] [Abstract][Full Text] [Related]